MiR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2

Maddalena Arigoni, Giuseppina Barutello, Federica Riccardo, Elisabetta Ercole, Daniela Cantarella, Francesca Orso, Laura Conti, Stefania Lanzardo, Daniela Taverna, Irene Merighi, Raffaele A. Calogero, Federica Cavallo, Elena Quaglino

Research output: Contribution to journalArticle

Abstract

In an attempt to reveal deregulated miRNAs associated with the progression of carcinomas developed in BALB-neuT transgenic mice, we found increased expression of miR-135b during malignancy. Relevantly, we observed that miR-135b is up-regulated in basal or normal-like human breast cancers, and it correlates with patient survival and early metastatization. Therefore, we investigated its biological functions by modulating its expression (up- or down-regulation) in mammary tumor cells. Although no effect was observed on proliferation in cell culture and in orthotopically injected mice, miR-135b was able to control cancer cell stemness in a mammosphere assay, anchorage-independent growth in vitro, and lung cancer cell dissemination in mice after tail vein injections. Focusing on the miR-135b molecular mechanism, we observed that miR-135b controls malignancy via its direct targets, midline 1 (MID1) and mitochondrial carrier homolog 2 (MTCH2), as proved by biochemical and functional rescuing/phenocopying experiments. Consistently, an anti-correlation between miR-135b and MID1 or MTCH2 was found in human primary tumor samples. In conclusion, our research led us to the identification of miR-135b and its targets, MID1 and MTCH2, as relevant coordinators of mammary gland tumor progression.

Original languageEnglish
Pages (from-to)2058-2070
Number of pages13
JournalAmerican Journal of Pathology
Volume182
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Breast Neoplasms
Neoplasms
Human Mammary Glands
MicroRNAs
Transgenic Mice
Tail
Veins
Lung Neoplasms
Up-Regulation
Down-Regulation
Cell Culture Techniques
Carcinoma
Injections
Survival
Growth
Research
In Vitro Techniques
Mouse Mirn135 microRNA

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

MiR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2. / Arigoni, Maddalena; Barutello, Giuseppina; Riccardo, Federica; Ercole, Elisabetta; Cantarella, Daniela; Orso, Francesca; Conti, Laura; Lanzardo, Stefania; Taverna, Daniela; Merighi, Irene; Calogero, Raffaele A.; Cavallo, Federica; Quaglino, Elena.

In: American Journal of Pathology, Vol. 182, No. 6, 06.2013, p. 2058-2070.

Research output: Contribution to journalArticle

Arigoni, M, Barutello, G, Riccardo, F, Ercole, E, Cantarella, D, Orso, F, Conti, L, Lanzardo, S, Taverna, D, Merighi, I, Calogero, RA, Cavallo, F & Quaglino, E 2013, 'MiR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2', American Journal of Pathology, vol. 182, no. 6, pp. 2058-2070. https://doi.org/10.1016/j.ajpath.2013.02.046
Arigoni, Maddalena ; Barutello, Giuseppina ; Riccardo, Federica ; Ercole, Elisabetta ; Cantarella, Daniela ; Orso, Francesca ; Conti, Laura ; Lanzardo, Stefania ; Taverna, Daniela ; Merighi, Irene ; Calogero, Raffaele A. ; Cavallo, Federica ; Quaglino, Elena. / MiR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2. In: American Journal of Pathology. 2013 ; Vol. 182, No. 6. pp. 2058-2070.
@article{c3ccc82e301742c2bde16e297f0d60f4,
title = "MiR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2",
abstract = "In an attempt to reveal deregulated miRNAs associated with the progression of carcinomas developed in BALB-neuT transgenic mice, we found increased expression of miR-135b during malignancy. Relevantly, we observed that miR-135b is up-regulated in basal or normal-like human breast cancers, and it correlates with patient survival and early metastatization. Therefore, we investigated its biological functions by modulating its expression (up- or down-regulation) in mammary tumor cells. Although no effect was observed on proliferation in cell culture and in orthotopically injected mice, miR-135b was able to control cancer cell stemness in a mammosphere assay, anchorage-independent growth in vitro, and lung cancer cell dissemination in mice after tail vein injections. Focusing on the miR-135b molecular mechanism, we observed that miR-135b controls malignancy via its direct targets, midline 1 (MID1) and mitochondrial carrier homolog 2 (MTCH2), as proved by biochemical and functional rescuing/phenocopying experiments. Consistently, an anti-correlation between miR-135b and MID1 or MTCH2 was found in human primary tumor samples. In conclusion, our research led us to the identification of miR-135b and its targets, MID1 and MTCH2, as relevant coordinators of mammary gland tumor progression.",
author = "Maddalena Arigoni and Giuseppina Barutello and Federica Riccardo and Elisabetta Ercole and Daniela Cantarella and Francesca Orso and Laura Conti and Stefania Lanzardo and Daniela Taverna and Irene Merighi and Calogero, {Raffaele A.} and Federica Cavallo and Elena Quaglino",
year = "2013",
month = "6",
doi = "10.1016/j.ajpath.2013.02.046",
language = "English",
volume = "182",
pages = "2058--2070",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - MiR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2

AU - Arigoni, Maddalena

AU - Barutello, Giuseppina

AU - Riccardo, Federica

AU - Ercole, Elisabetta

AU - Cantarella, Daniela

AU - Orso, Francesca

AU - Conti, Laura

AU - Lanzardo, Stefania

AU - Taverna, Daniela

AU - Merighi, Irene

AU - Calogero, Raffaele A.

AU - Cavallo, Federica

AU - Quaglino, Elena

PY - 2013/6

Y1 - 2013/6

N2 - In an attempt to reveal deregulated miRNAs associated with the progression of carcinomas developed in BALB-neuT transgenic mice, we found increased expression of miR-135b during malignancy. Relevantly, we observed that miR-135b is up-regulated in basal or normal-like human breast cancers, and it correlates with patient survival and early metastatization. Therefore, we investigated its biological functions by modulating its expression (up- or down-regulation) in mammary tumor cells. Although no effect was observed on proliferation in cell culture and in orthotopically injected mice, miR-135b was able to control cancer cell stemness in a mammosphere assay, anchorage-independent growth in vitro, and lung cancer cell dissemination in mice after tail vein injections. Focusing on the miR-135b molecular mechanism, we observed that miR-135b controls malignancy via its direct targets, midline 1 (MID1) and mitochondrial carrier homolog 2 (MTCH2), as proved by biochemical and functional rescuing/phenocopying experiments. Consistently, an anti-correlation between miR-135b and MID1 or MTCH2 was found in human primary tumor samples. In conclusion, our research led us to the identification of miR-135b and its targets, MID1 and MTCH2, as relevant coordinators of mammary gland tumor progression.

AB - In an attempt to reveal deregulated miRNAs associated with the progression of carcinomas developed in BALB-neuT transgenic mice, we found increased expression of miR-135b during malignancy. Relevantly, we observed that miR-135b is up-regulated in basal or normal-like human breast cancers, and it correlates with patient survival and early metastatization. Therefore, we investigated its biological functions by modulating its expression (up- or down-regulation) in mammary tumor cells. Although no effect was observed on proliferation in cell culture and in orthotopically injected mice, miR-135b was able to control cancer cell stemness in a mammosphere assay, anchorage-independent growth in vitro, and lung cancer cell dissemination in mice after tail vein injections. Focusing on the miR-135b molecular mechanism, we observed that miR-135b controls malignancy via its direct targets, midline 1 (MID1) and mitochondrial carrier homolog 2 (MTCH2), as proved by biochemical and functional rescuing/phenocopying experiments. Consistently, an anti-correlation between miR-135b and MID1 or MTCH2 was found in human primary tumor samples. In conclusion, our research led us to the identification of miR-135b and its targets, MID1 and MTCH2, as relevant coordinators of mammary gland tumor progression.

UR - http://www.scopus.com/inward/record.url?scp=84878236258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878236258&partnerID=8YFLogxK

U2 - 10.1016/j.ajpath.2013.02.046

DO - 10.1016/j.ajpath.2013.02.046

M3 - Article

C2 - 23623609

AN - SCOPUS:84878236258

VL - 182

SP - 2058

EP - 2070

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 6

ER -